2021 Revenues ($USD) : $5,632,300,000
2021 R&D spend : $276,300,000
2021 Number of Employees : 6,350
Fiscal Year End : 9/25/2021
Key People : Stephen MacMillan, chair, president and CEO; Erik Anderson, president, global services; Monica Aguirre Berthelot, chief of staff; Patrick Brady, SVP, global supply chain, quality and regulatory; Sean Daugherty, president, breast/skeletal health and GYN surgical solutions; John Griffin, general counsel; Lisa Hellmann, SVP, human resources; Jennifer Meade, division president, breast and skeletal health solutions; Essex Mitchell, division president, GYN surgical solutions; Karleen Oberton, CFO; Kevin Thornal, division president, diagnostic solutions; Jay Stein, cofounder, chairperson emeritus, SVP & chief technology officer; Jan Verstreken, group president, international; Michael Watts, VP, investor relations and corporate communications (outgoing).

About the company: Founded in 1985, Marlborough, Massachusetts–based Hologic develops and manufactures diagnostics products, imaging systems, and surgical products focused on women's health and well-being through early detection and treatment. The company successfully pivoted toward more general diagnostics during the COVID-19 pandemic, becoming a major provider of tests and testing machines for the novel coronavirus. The resulting influx of cash enabled Hologic to reactivate full-time R&D operations and send business development teams shopping for M&A opportunities. Deals completed or in the works include $64 million for Somatex Medical Technologies, which develops minimally invasive devices for tumor diagnostics, biopsy and interventional specialties; $159 million for Diagenode, a PCR assay manufacturer; $808 million for Mobidiag, a Finnish-French developer of molecular low-plex and high-plex testing; and $160 million for Bolder Surgical, a developer and manufacturer of advanced energy vessel-sealing surgical devices.  –JH